Literature DB >> 17609621

Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation.

Cécile Brachet1, Claudine Heinrichs, Sylvie Tenoutasse, Christine Devalck, Nadira Azzi, Alina Ferster.   

Abstract

The aim of this study is to describe the growth, pubertal development, and gonadal function of a cohort of 30 sickle cell disease children who underwent bone marrow transplantation. They all received the standard pretransplant conditioning regimen of busulfan (14 or 16 mg/kg) and cyclophosphamide (200 mg/kg). Growth was normal both before and after transplant. Seven out of 10 girls had severe ovarian failure and requirement for estrogen replacement. Three out of 10 girls recovered some ovarian function posttransplant, with spontaneous pubertal development, menses, and 1 successful normal pregnancy. Follicle-stimulating hormone (FSH) serum levels were very high during spontaneous puberty and slowly normalized thereafter in these 3 patients. The 3 girls with ovarian function recovery differed from the 7 others by the lower busulphan dose of the conditioning regimen they received (14 rather than 16 mg/kg). All boys showed spontaneous pubertal development. However, most of them had small testis and elevated serum FSH levels, reflecting germinal epithelium damage. Testosterone level was low normal and luteinizing hormone elevated, reflecting Leydig cell insufficiency. In conclusion, 7/10 girls had complete gonadal failure and most of the boys had spontaneous puberty but germinal epithelial failure. Serum FSH levels showed important variations over time in the same patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609621     DOI: 10.1097/MPH.0b013e31806451ac

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  17 in total

1.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD).

Authors:  Courtney D Fitzhugh; Shira Perl; Matthew M Hsieh
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

3.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Sickle cell disease: primum non nocere (first do no harm).

Authors:  Mariane de Montalembert; Irene Roberts
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

5.  Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.

Authors:  Roman Crazzolara; Gabriele Kropshofer; Oskar A Haas; Susanne Matthes-Martin; Leo Kager
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

6.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

7.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

Review 8.  Blood and marrow transplantation for sickle cell disease: overcoming barriers to success.

Authors:  Javier Bolaños-Meade; Robert A Brodsky
Journal:  Curr Opin Oncol       Date:  2009-03       Impact factor: 3.645

9.  Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.

Authors:  Mark C Walters; Karen Hardy; Sandie Edwards; Thomas Adamkiewicz; James Barkovich; Francoise Bernaudin; George R Buchanan; Nancy Bunin; Roswitha Dickerhoff; Roger Giller; Paul R Haut; John Horan; Lewis L Hsu; Naynesh Kamani; John E Levine; David Margolis; Kwaku Ohene-Frempong; Melinda Patience; Rupa Redding-Lallinger; Irene A G Roberts; Zora R Rogers; Jean E Sanders; J Paul Scott; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-12       Impact factor: 5.742

Review 10.  Blood and marrow transplantation for sickle cell disease: is less more?

Authors:  Javier Bolaños-Meade; Robert A Brodsky
Journal:  Blood Rev       Date:  2014-08-27       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.